SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Jacqueline du Pré Synthetic CCD — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJacqueline Mary du Pré
Date of birth1945-01-26
IdentifiersMRN HR-ML039-SYN-TD; SSN (made up) 000-39-7062
Document date2026-11-01
AuthorImogen Thackeray-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Reason for Visit

Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spine. Concerns: For three weeks the fingers of both hands have been numb and tingling, worse on the left; she cannot feel the strings properly, loses her place on the fingerboard and has dropped her bow twice; an electric feeling runs down her back when she bends her head; tired by mid-afternoon for months; A similar month of tingling in her fingers 18 months ago was put down to overwork and stress, and settled; She wants to know what is wrong, and whether she will be able to play again. [S]

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Medications

MedicationFrequencyRouteDatesStatusEvidence
Nitrofurantoin macrocrystals 100 mg oral capsule, one capsule by mouth twice daily with food for 5 daysOne capsule twice daily for 5 daysOral route1973-06-15 to 1973-06-19completedS
Methylprednisolone 1000 mg injection, 1 g intravenously over one hour once daily for 3 days1 g daily for 3 daysIntravenous route1973-03-24 to 1973-03-26completedS
Cholecalciferol (vitamin D3) 4000 unit (100 microgram) oral capsule, one capsule by mouth dailyOne capsule dailyOral route1973-03-23activeS
Ocrelizumab 30 mg/mL injection: first dose as 300 mg intravenously on day 1 and day 15, then 600 mg intravenously every 6 months, with methylprednisolone 100 mg, an antihistamine and acetaminophen before each infusion300 mg on days 1 and 15, then 600 mg every 6 monthsIntravenous route1973-04-13activeS

Procedures

ProcedureDatesStatusEvidence
MRI of the brain with and without gadolinium: 11 ovoid T2-hyperintense lesions, 3 mm to 9 mm, eight periventricular (several perpendicular to the ventricles), two juxtacortical and one in the right middle cerebellar peduncle; one periventricular lesion enhances; most lesions show a central vein; no mass, no meningeal enhancement1973-03-12 to 1973-03-12completedS
MRI of the cervical and thoracic spine with and without gadolinium (same session): a short dorsal lesion at C3 to C4, less than one vertebral segment long and occupying under half the cord's cross-section, with patchy enhancement; a second, non-enhancing lesion at T7; no cord swelling or compression1973-03-12 to 1973-03-12completedS
Lumbar puncture: clear fluid; white cells 6 per microliter (lymphocytes), protein 42 mg/dL, glucose normal; six oligoclonal bands in the cerebrospinal fluid not present in the serum; IgG index 0.86 (raised). Serum aquaporin-4 IgG by cell-based assay negative; HIV and syphilis serology negative1973-03-16 to 1973-03-16completedS
Advance care planning conversation, about 15 minutes1973-09-14 to 1973-09-14completedS
Occupational therapy assessment and program for hand function and fatigue: fine-motor and sensory re-education exercises for the fingers, graded return to practice in short blocks with rests, posture at the instrument, and energy management1973-03-30 to 1973-03-30completedS
Re-baseline MRI of the brain with and without gadolinium three months after starting ocrelizumab: no new or enlarging T2 lesions and no enhancing lesions; the previously enhancing periventricular lesion is smaller1973-07-08 to 1973-07-08completedS

Immunizations

DateVaccineStatusEvidence
1970-02-06Tdap vaccinecompletedS
1973-09-14Influenza vaccine, this season (inactivated)completedS
1973-09-14COVID-19 mRNA vaccine, this season's formulacompletedS
1973-03-23Pneumococcal conjugate vaccine (PCV20), before B-cell therapycompletedS
1973-03-23Recombinant zoster vaccine, dose 1 of 2, before B-cell therapycompletedS
1973-03-23Hepatitis B vaccine (adjuvanted, two-dose series), dose 1, before B-cell therapycompletedS
1973-04-27Hepatitis B vaccine (adjuvanted, two-dose series), dose 2completedS
1973-07-13Recombinant zoster vaccine, dose 2 of 2completedS

Past Medical History

Historical biography with true dates. These events are not part of the synthetic care timeline.

No historical medical events are recorded.

Family History

No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.

Health Concerns

ConcernStatusEvidence
For three weeks the fingers of both hands have been numb and tingling, worse on the left; she cannot feel the strings properly, loses her place on the fingerboard and has dropped her bow twice; an electric feeling runs down her back when she bends her head; tired by mid-afternoon for monthsactiveS
A similar month of tingling in her fingers 18 months ago was put down to overwork and stress, and settledactiveS
She wants to know what is wrong, and whether she will be able to play againactiveS

Assessment

Most recent measures: Hemoglobin [Mass/volume] in Blood 13.7 on 1973-10-12; Leukocytes [#/volume] in Blood by Automated count 6 on 1973-10-12; Lymphocytes [#/volume] in Blood by Automated count 1.4 on 1973-10-12; Platelets [#/volume] in Blood by Automated count 238 on 1973-10-12; Sodium [Moles/volume] in Serum or Plasma 140 on 1973-03-09; Potassium [Moles/volume] in Serum or Plasma 4.2 on 1973-03-09; Creatinine [Mass/volume] in Serum or Plasma 0.7 on 1973-10-12; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M 121 on 1973-10-12; Glucose [Mass/volume] in Serum or Plasma 90 on 1973-04-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 18 on 1973-10-12; Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma 20 on 1973-10-12; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 468 on 1973-03-09; Thyrotropin [Units/volume] in Serum or Plasma 1.6 on 1973-03-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 1973-03-09; 9-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox] 18.5 on 1973-10-12; 9-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox] 19.5 on 1973-10-12; 25-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma 38 on 1973-10-12; IgG [Mass/volume] in Serum or Plasma 930 on 1973-10-12; IgM [Mass/volume] in Serum or Plasma 46 on 1973-10-12; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 1973-10-12; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 3 on 1973-10-12; C reactive protein [Mass/volume] in Serum or Plasma 14 on 1973-06-15; CD19 cells [#/volume] in Blood 3 on 1973-07-13; Hepatitis B virus surface Ab [Units/volume] in Serum 6 on 1973-10-12 [S]

Strengths and supports: engagement in care [S]

Problems

ProblemClinical statusVerificationCodeProvenance
Numbness, tingling and loss of position sense in the fingers of both hands for three weeks, worse on the left, with clumsiness that makes her lose her place on the fingerboard, an electric feeling down the spine on bending the neck (Lhermitte's sign), and fatigue; a similar month of tingling in the fingers 18 months ago settled on its own. A lesion of the cervical spinal cord must be found: MRI of the brain and spine with contrast booked this weekresolvedconfirmed R20.2S — Synthetic presenting problem anchored to her documented loss of sensation in her fingers and fatigue. Superseded by the diagnosis at the second visit.
Relapsing-remitting multiple sclerosis, active: a current relapse (partial cervical myelitis at C3 to C4 with sensory loss and clumsiness of the hands) after an earlier sensory episode; dissemination in space and time on MRI, with an enhancing cord lesion and an enhancing brain lesion; CSF-specific oligoclonal bands; aquaporin-4 antibody negative; meets the 1964 McDonald criteria and the 1971 revision; synthetic modern detail linked to her documented diagnosisactiveconfirmed G35.AS — Synthetic course, imaging and laboratory detail; linked to her documented diagnosis in October 1973.
Vitamin D deficiency: 25-hydroxyvitamin D 16 ng/mL; replacement to correct the deficiency, not as a treatment for multiple sclerosisactiveconfirmed E55.9S — Synthetic finding.
Acute uncomplicated cystitis (Escherichia coli) seven weeks after the first ocrelizumab course, with a pseudo-relapse: two days of returning tingling in the fingers with a low fever and no new neurological deficit; resolvedresolvedconfirmed N30.00S — Synthetic intercurrent infection; not a historical claim.

Results

DateMeasureValueUnitReference rangeFlagProvenance
1973-03-09Hemoglobin [Mass/volume] in Blood13.4g/dL12-15.5 g/dLNormalS
1973-03-09Leukocytes [#/volume] in Blood by Automated count6.410*3/uL4-11 10*3/uLNormalS
1973-03-09Lymphocytes [#/volume] in Blood by Automated count1.910*3/uL1-4.8 10*3/uLNormalS
1973-03-09Platelets [#/volume] in Blood by Automated count24610*3/uL150-400 10*3/uLNormalS
1973-03-09Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1973-03-09Potassium [Moles/volume] in Serum or Plasma4.2mmol/L3.5-5.1 mmol/LNormalS
1973-03-09Creatinine [Mass/volume] in Serum or Plasma0.72mg/dL0.59-1.04 mg/dLNormalS
1973-03-09Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M117mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1973-03-09Glucose [Mass/volume] in Serum or Plasma86mg/dL70-99 mg/dLNormalS
1973-03-09Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma16U/L7-35 U/LNormalS
1973-03-09Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma19U/L8-35 U/LNormalS
1973-03-09Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma468pg/mL232-1245 pg/mLNormalS
1973-03-09Thyrotropin [Units/volume] in Serum or Plasma1.6m[IU]/L0.45-4.5 mIU/LNormalS
1973-03-09Patient Health Questionnaire 2 item (PHQ-2) total score [Reported]1{score}S
1973-03-099-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]26sS
1973-03-099-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]33.5sS
1973-03-2325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma16ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientLowS
1973-03-23IgG [Mass/volume] in Serum or Plasma1080mg/dL700-1600 mg/dLNormalS
1973-03-23IgM [Mass/volume] in Serum or Plasma124mg/dL40-230 mg/dLNormalS
1973-03-23Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S
1973-03-23Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]6{score}S
1973-03-239-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]24.5sS
1973-03-239-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]31sS
1973-04-27Hemoglobin [Mass/volume] in Blood13.6g/dL12-15.5 g/dLNormalS
1973-04-27Leukocytes [#/volume] in Blood by Automated count7.910*3/uL4-11 10*3/uLNormalS
1973-04-27Lymphocytes [#/volume] in Blood by Automated count1.610*3/uL1-4.8 10*3/uLNormalS
1973-04-27Platelets [#/volume] in Blood by Automated count25210*3/uL150-400 10*3/uLNormalS
1973-04-27Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
1973-04-27Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma21U/L7-35 U/LNormalS
1973-04-27Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma22U/L8-35 U/LNormalS
1973-04-27Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]5{score}S
1973-04-279-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]20.5sS
1973-04-279-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]23sS
1973-06-15Leukocytes [#/volume] in Blood by Automated count10.210*3/uL4-11 10*3/uLNormalS
1973-06-15C reactive protein [Mass/volume] in Serum or Plasma14mg/L<=5 mg/LHighS
1973-07-13Hemoglobin [Mass/volume] in Blood13.5g/dL12-15.5 g/dLNormalS
1973-07-13Leukocytes [#/volume] in Blood by Automated count6.110*3/uL4-11 10*3/uLNormalS
1973-07-13Lymphocytes [#/volume] in Blood by Automated count1.510*3/uL1-4.8 10*3/uLNormalS
1973-07-13Platelets [#/volume] in Blood by Automated count24010*3/uL150-400 10*3/uLNormalS
1973-07-13CD19 cells [#/volume] in Blood3/uL100-500 /uLLowS
1973-07-13IgG [Mass/volume] in Serum or Plasma990mg/dL700-1600 mg/dLNormalS
1973-07-1325-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma34ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientNormalS
1973-07-13Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]4{score}S
1973-07-139-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]19sS
1973-07-139-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]20.5sS
1973-09-14Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1973-10-12Hemoglobin [Mass/volume] in Blood13.7g/dL12-15.5 g/dLNormalS
1973-10-12Leukocytes [#/volume] in Blood by Automated count610*3/uL4-11 10*3/uLNormalS
1973-10-12Lymphocytes [#/volume] in Blood by Automated count1.410*3/uL1-4.8 10*3/uLNormalS
1973-10-12Platelets [#/volume] in Blood by Automated count23810*3/uL150-400 10*3/uLNormalS
1973-10-12Creatinine [Mass/volume] in Serum or Plasma0.7mg/dL0.59-1.04 mg/dLNormalS
1973-10-12Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1968)/1.73 sq M121mL/min/{1.73_m2}>=60 mL/min/1.73 m²NormalS
1973-10-12Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma18U/L7-35 U/LNormalS
1973-10-12Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma20U/L8-35 U/LNormalS
1973-10-12IgG [Mass/volume] in Serum or Plasma930mg/dL700-1600 mg/dLNormalS
1973-10-12IgM [Mass/volume] in Serum or Plasma46mg/dL40-230 mg/dLNormalS
1973-10-1225-Hydroxyvitamin D3+25-Hydroxyvitamin D2 [Mass/volume] in Serum or Plasma38ng/mLBelow 20 ng/mL deficient; 20 to 29 insufficientNormalS
1973-10-12Hepatitis B virus surface Ab [Units/volume] in Serum6m[IU]/mL10 mIU/mL or more is protectiveLowS
1973-10-12Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]3{score}S
1973-10-12Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ]3{score}S
1973-10-129-Hole Pegboard Dexterity Test Time Hand - right [NIH Toolbox]18.5sS
1973-10-129-Hole Pegboard Dexterity Test Time Hand - left [NIH Toolbox]19.5sS

Social History

Vital Signs

DateMeasureValueUnitProvenance
1973-03-09Body height173cmS
1973-03-09Body weight63.5kgS
1973-03-09Body mass index (BMI) [Ratio]21.2kg/m2S
1973-03-09Systolic blood pressure112mm[Hg]S
1973-03-09Diastolic blood pressure70mm[Hg]S
1973-03-09Heart rate74/minS
1973-03-09Respiratory rate14/minS
1973-03-09Body temperature36.6CelS
1973-03-09Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-03-23Body height173cmS
1973-03-23Body weight63.4kgS
1973-03-23Body mass index (BMI) [Ratio]21.2kg/m2S
1973-03-23Systolic blood pressure114mm[Hg]S
1973-03-23Diastolic blood pressure72mm[Hg]S
1973-03-23Heart rate76/minS
1973-03-23Respiratory rate14/minS
1973-03-23Body temperature36.7CelS
1973-03-23Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-04-27Body height173cmS
1973-04-27Body weight64.6kgS
1973-04-27Body mass index (BMI) [Ratio]21.6kg/m2S
1973-04-27Systolic blood pressure118mm[Hg]S
1973-04-27Diastolic blood pressure74mm[Hg]S
1973-04-27Heart rate72/minS
1973-04-27Respiratory rate14/minS
1973-04-27Body temperature36.6CelS
1973-04-27Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-07-13Body height173cmS
1973-07-13Body weight64kgS
1973-07-13Body mass index (BMI) [Ratio]21.4kg/m2S
1973-07-13Systolic blood pressure110mm[Hg]S
1973-07-13Diastolic blood pressure70mm[Hg]S
1973-07-13Heart rate70/minS
1973-07-13Respiratory rate14/minS
1973-07-13Body temperature36.6CelS
1973-07-13Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-10-12Body height173cmS
1973-10-12Body weight63.8kgS
1973-10-12Body mass index (BMI) [Ratio]21.3kg/m2S
1973-10-12Systolic blood pressure112mm[Hg]S
1973-10-12Diastolic blood pressure70mm[Hg]S
1973-10-12Heart rate68/minS
1973-10-12Respiratory rate14/minS
1973-10-12Body temperature36.5CelS
1973-10-12Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-06-15Body height173cmS
1973-06-15Body weight63.6kgS
1973-06-15Body mass index (BMI) [Ratio]21.3kg/m2S
1973-06-15Systolic blood pressure116mm[Hg]S
1973-06-15Diastolic blood pressure72mm[Hg]S
1973-06-15Heart rate92/minS
1973-06-15Respiratory rate16/minS
1973-06-15Body temperature37.8CelS
1973-06-15Oxygen saturation in Arterial blood by Pulse oximetry99%S
1973-09-14Body height173cmS
1973-09-14Body weight63.9kgS
1973-09-14Body mass index (BMI) [Ratio]21.4kg/m2S
1973-09-14Systolic blood pressure110mm[Hg]S
1973-09-14Diastolic blood pressure70mm[Hg]S
1973-09-14Heart rate68/minS
1973-09-14Respiratory rate14/minS
1973-09-14Body temperature36.6CelS
1973-09-14Oxygen saturation in Arterial blood by Pulse oximetry99%S

Encounters

DatePurposeStatusProvenance
1973-03-09Three weeks of numbness and clumsiness in the fingers of both hands, with Lhermitte's sign and fatigue, in a professional cellist of 28: examination, blood tests, and urgent MRI of the brain and spinefinishedS
1973-03-23Diagnosis of relapsing-remitting multiple sclerosis: neurology consultation, treatment of the relapse, choice of high-efficacy disease-modifying therapy, and vaccinations before B-cell therapyfinishedS
1973-04-27Second half-dose of the first ocrelizumab course: recovery of hand function, infusion reactions, vaccination, practice and workfinishedS
1973-07-13Three months on ocrelizumab: re-baseline MRI, B-cell depletion, fatigue, vitamin D and hand functionfinishedS
1973-10-12Six months: first 600 mg dose of ocrelizumab, no evidence of disease activity, immunoglobulins, vaccination response, pregnancy planning and her return to performingfinishedS
1973-06-15Same-day sick visit for cystitis with a pseudo-relapsefinishedS
1973-09-14Periodic adult preventive visit on B-cell therapyfinishedS

Plan of Treatment

InterventionStatusGuidelineProvenance
Neurology (multiple sclerosis) consultation within two weeks to review the MRI with her and make a diagnosis and plancompletedGL-AAN-DMT-2018, GL-NICE-NG220S
Urgent work-up of a sensory syndrome of both hands with Lhermitte's sign: MRI of the brain and cervical and thoracic spine with gadolinium within a week; blood count, chemistry, vitamin B12 and TSH; lumbar puncture for oligoclonal bands if the MRI is suggestive; return at once for weakness, unsteadiness, loss of bladder control or loss of visioncompletedGL-MCDONALD-2017, GL-MAGNIMS-2021, GL-NICE-NG220S
Relapse treatment: methylprednisolone 1 g intravenously daily for three days for a relapse that limits her hand function, after excluding infection; occupational therapy for hand function and energy managementcompletedGL-NICE-NG220, GL-ECTRIMS-2018S
Early high-efficacy disease-modifying therapy with ocrelizumab: 300 mg intravenously on days 1 and 15, then 600 mg every six months, with premedication; chosen over natalizumab because the JCV antibody is positive and over ofatumumab at her preference for twice-yearly infusions; before the first dose, hepatitis B screening, varicella and measles immunity, immunoglobulins, a pregnancy test, and inactivated vaccines at least two weeks ahead; contraception during treatmentcompletedGL-AAN-DMT-2018, GL-ECTRIMS-2018, GL-OPERA-2017, GL-AAN-VACC-2019S
Vitamin D: cholecalciferol 4000 units daily to correct deficiency, with a level after three months; not as a treatment for multiple sclerosiscompletedGL-NICE-NG220S
Monitoring on ocrelizumab: re-baseline MRI of the brain three to six months after starting, then yearly; blood count and immunoglobulins before each dose; infection and pseudo-relapse teaching; pregnancy planning, with conception timed after a dosecompletedGL-MAGNIMS-2021, GL-ECTRIMS-2018, GL-AAN-DMT-2018S
Fatigue, mood and work: screening for depression and sleep problems at each visit, plain explanations with written information, and a plan built around her practice, performing and teaching; she decides who is told and who receives each notecompletedGL-NICE-NG220, GL-USPSTF-DEP-2023S

Goals

GoalTargetStatusOutcomeProvenance
MRI of the brain and spine within one week and a neurology diagnosis within three weeks1973-03-23completedMRI in three days, lumbar puncture in a week, diagnosis and consultation at two weeksS
High-efficacy disease-modifying therapy started within six weeks of diagnosis, after screening and vaccinations1973-04-27completedOcrelizumab started three weeks after the diagnosis; PCV20, recombinant zoster and hepatitis B vaccines given firstS
Nine-hole peg times back to within 10 percent of normal in both hands, and full practice resumed1973-07-13completed19.0 seconds right and 20.5 seconds left at three months; practicing three hours a dayS
No evidence of disease activity at six months (no relapse, no new or enhancing MRI lesion, no disability progression)1973-10-12completedNo relapse; re-baseline MRI with no new or enhancing lesions; examination stableS
25-hydroxyvitamin D of 30 ng/mL or more1973-07-13completed34 ng/mL after 16 weeks of cholecalciferolS
PHQ-9 below 10 throughout1973-10-12completedPHQ-9 between 3 and 7S

Functional Status

Mental Status